Novo Nordisk (NVO) To Lower US Prices of its Injectable Wegovy Obesity Drug

The terms simplification for injectable Wegovy follows the company’s earlier announcement connected November 6, wherever it agreed with the US Administration to little cause prices opening successful 2026. However, the terms simplification timeline was accelerated arsenic Reuters connected November 17 reported the institution began cutting the terms of Wegovy from $499 to $349 per period for US cash-paying patients.

The study by Reuters besides noted the CEO of Novo Nordisk A/S (NYSE:NVO), Mike Doustdar, pledging to spell “all in” with its upcoming oral weight-loss pill, expected to beryllium approved by the extremity of the year. This is important arsenic the institution is locked successful contention with Eli Lilly and is looking to debar repeating the proviso issues it faced with the motorboat of Wegovy successful 2021. CEO Mike Doustdar said,

​”We person much than capable pills this time, truthful we’re going to spell each successful and truly marque this happen.”

​Wall Street has a mixed sentiment connected Novo Nordisk A/S (NYSE:NVO). On November 17, Evan Seigerman from BMO Capital lowered the firm’s terms people connected the banal from $55 to $50, portion reiterating a Hold rating. Earlier connected November 13, Kerry Holford from Berenberg Bank had besides lowered the terms people connected the banal from $67 to $62, but maintained a Buy rating.

​Novo Nordisk A/S (NYSE:NVO) is simply a planetary healthcare institution focused chiefly connected diabetes and obesity care.

While we admit the imaginable of NVO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.